nct-501 and olaparib

nct-501 has been researched along with olaparib* in 1 studies

*olaparib: an antineoplastic agent, Poly(ADP-ribose) Polymerase inhibitor [MeSH]

Other Studies

1 other study(ies) available for nct-501 and olaparib

Article	Year
ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 Molecular cancer therapeutics, 2020, Volume: 19, Issue:1 Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; DNA End-Joining Repair; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Mice, Nude; Mutation; Nuclear Proteins; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Retinal Dehydrogenase; Theophylline; Transcription Factors; Transfection; Xenograft Model Antitumor Assays	2020

Article

Year

ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2

Molecular cancer therapeutics, 2020, Volume: 19, Issue:1

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with

Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; DNA End-Joining Repair; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Mice, Nude; Mutation; Nuclear Proteins; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Retinal Dehydrogenase; Theophylline; Transcription Factors; Transfection; Xenograft Model Antitumor Assays

2020